Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PLUS THERAPEUTICS, INC. Director's Dealing 2016

Jun 15, 2016

34301_dirs_2016-06-15_114c4b67-0f70-4700-971b-c78a2084d154.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTORI THERAPEUTICS, INC. (CYTX)
CIK: 0001095981
Period of Report: 2016-06-15

Reporting Person: RICKEY DAVID (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-06-15 Common Stock X 6000 Acquired 24004 Indirect
2016-06-15 Common Stock X 16000 Acquired 71226 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-06-15 Subscription Rights (Right to Buy) $2.55 X 6000 Disposed 2016-06-10 See Footnote (6000) Indirect
2016-06-15 Subscription Rights (Righ to Buy) $2.55 X 16000 Disposed 2016-06-10 See Footnote (16000) Indirect
2016-06-15 Warrants (Right to Buy) $3.06 X 3000 Acquired 2018-12-14 Common Stock (3000) Indirect
2016-06-15 Warrants (Right to Buy) $3.06 X 8000 Acquired 2018-12-14 Common Stock (8000) Indirect

Footnotes

F1: These securities are owned by the Dave Rickey and Daughters Foundation Charitable Trust.

F2: These securities are owned by The David M Rickey Trust u/a DTD 5/8/2002, David M. Rickey Trustee.

F3: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company) to all holders of the Company's common stock. The subscription rights entitled each recipient thereof to purchase units ("Units"). Each Unit consists of one share of the Company's common stock and 0.5 of a warrant, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $2.55

F4: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $3.06 from the date of issuance through December 14, 2018.